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Abstract
Background: The effect of thrombus aspiration on mortality is still controversial, with results 
which are often inconsistent in different randomized trials, real world registries and differ-
ent follow-up duration. The aim of this analysis was to assess the effect on 30-day and 1-year 
mortality of thrombus aspiration during primary percutaneous coronary intervention (pPCI) 
for ST-elevation myocardial infarction (STEMI) compared with conventional PCI.
Methods: We used data from all the consecutive STEMI patients treated either with conven-
tional PCI or thrombus aspiration between January 1, 2004 and January 1, 2012. Propensity 
matching score was calculated on the basis of several baseline and procedural characteristics 
in order to predict the probability for each patient of having been treated with thrombus aspira-
tion. This propensity score analysis was used in order to select a cohort of patients treated with 
thrombus aspiration matched one-to-one with patients treated with conventional PCI.
Results: In total, 744 (53.1%) patients out of 1,400 enrolled were treated with thrombus as-
piration. In the matched cohort, at 30-day follow-up 6.3% of patients in the conventional PCI 
group died compared to 4.7% in the thrombus aspiration group. The unadjusted hazard ratio 
(HR) for 30-day mortality was 1.01 (95% CI 0.33–3.14, p = 0.985). In the same cohort, 10.7% 
of patients died at 1-year in the conventional PCI group compared to 5.2% in the thrombus as-
piration group. The 1-year unadjusted hazard ratio for mortality was 0.47 (95% CI 0.25–0.90, 
p = 0.025). The HR changed and was no longer significant after adjustment for differences in 
the use of glycoprotein (GP) IIb/IIIa inhibitors, lesion pre-dilatation and pre-procedural TIMI 
flow: 0.71 (95% CI 0.36–1.39, p = 0.322).
Conclusions: Thrombus aspiration does not influence 30-day mortality, however it is associa-
ted with 1-year survival benefit. GP IIb/IIIa inhibitors and thrombus aspiration may have an 
important synergistic role in leading to this long-term benefit. (Cardiol J 2015; 22, 3: 306–314)
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Introduction
Primary percutaneous coronary intervention 
(pPCI) has become a treatment of choice for ST-
-elevation myocardial infarction (STEMI) since 
studies have demonstrated its superiority over 
conventional thrombolytic treatment [1]. Coronary 
stents and adjunctive pharmacologic agents have 
improved the effect of PCI [2, 3] restoring a nor-
mal anterograde blood flow in the vast majority of 
patients. However, dislodgement of atherothrom-
botic material from coronary lesions during PCI 
can result in distal embolization, termed the “no-
reflow phenomenon, in 12–39% of patients” [4, 5]. 
Numerous adjunctive devices and drugs have been 
developed to remove thrombi or protect against 
distal embolization during PCI [6, 7]. Though stud-
ies so far have failed to demonstrate a benefit for 
distal protection devices, evidence to date appears 
to be more promising for thrombectomy devices 
as recognized by international guidelines [8, 9].
Nevertheless, the recent TASTE trial showed 
no benefit on 30-day mortality rate with routine 
thrombus aspiration in STEMI patients undergoing 
PCI [10]. Similarly, the INFUSE-AMI (Intracoro-
nary Abciximab and Aspiration Thrombectomy in 
Patients with Large Anterior Myocardial Infarction) 
[11] showed no differences in final infarct size at 
30-day between STEMI patients treated with pPCI 
alone or pPCI and thrombus aspiration. In these 
trials, despite broad inclusion criteria, the highest-
risk patients, such as those with cardiogenic shock, 
were underrepresented. Moreover, as pointed out 
by Byrne and Kastrati [12] the potential benefits 
of thrombus aspiration mediated through enhanced 
myocardial salvage and favorable remodeling may 
not be captured at 30-day but may be expected to 
emerge during the first year after infarction.
We therefore investigated the effect of adjunc-
tive thrombus aspiration on 30-day and 1-year 
mortality in a large propensity matched STEMI 
patient cohort.
Methods
The data analyzed in this study were obtained 
from STEMI patients (within 12 h from the onset 
of symptoms, without restriction based on age or 
clinical status at presentation) who underwent 
pPCI at the Careggi Hospital, University of Flor-
ence between January 1, 2004, and January 1, 2012. 
Data were collected in a prospective registry.
In the urban area of Florence, Acute Myocar-
dial Infarction operative model assumes that pa-
tients are first evaluated by the medical emergency 
system staff in the pre-hospital setting and then 
directly admitted to the catheterization laboratory 
of our tertiary center (Cath Lab) or transferred 
there after a rapid stabilization in Emergency 
Department. After pPCI, they are admitted to our 
Intensive Cardiac Care Unit (ICCU).
The diagnosis of STEMI was based on the 
criteria of the American College of Cardiology/ 
/American Heart Association [9].
According to our Cath Lab’s protocol, throm-
bus aspiration was performed in presence of the 
following conditions: (1) Thrombolysis In Myo-
cardial Infarction (TIMI) grade 0 to 1 flow; (2) An 
infarction-related artery minimal reference diam-
eter of at least 2.5 mm.
Mechanical (Export Medtronic Device) or 
Rheolytic (AngioJet Rheolytic Thrombectomy Sys-
tem, Medrad Interventional/Possis, Minneapolis, 
Minnesota) thrombus aspiration was performed ac-
cording to the interventional cardiologist’s discre-
tion [13, 14]. As a general rule, rheolytic thrombus 
aspiration was preferred to mechanical thrombus 
aspiration in presence of a large thrombus burden 
in a proximal segment of a large coronary artery.
All patients were pretreated with aspirin 
300 mg orally or 500 mg i.v. and clopidogrel 600 mg 
or prasugrel 60 mg or ticagrelor 180 mg orally. 
Heparin was given as an initial bolus of 70 U/kg i.v., 
and additional boluses were administered during 
the procedure to achieve an activated clotting time 
of 200 to 250 s. Glycoprotein (GP) IIb/IIIa inhibitors 
were administered according to the interventional 
cardiologist’s discretion during revascularization in 
the Cath Lab. After the procedure, patients were 
treated with aspirin (100 to 325 mg daily orally 
indefinitely) and clopidogrel (75 mg daily orally for 
12 months) or prasugrel (10 mg orally for 12 months) 
or ticagrelor (90 mg orally twice daily for 12 months). 
Other drugs such as beta-blockers, angiotensin-
converting enzyme inhibitors, and statins were used 
in accordance with standard guidelines.
Primary PCI was performed according to 
standard clinical practice using a femoral artery 
access with a 6 F sheath insertion in most of pa-
tients; in about one third of patients radial approach 
was used. Procedural success was defined as 
a post-procedure infarct stenosis < 20% together 
with TIMI grade 3 flow. Failure PCI was defined 
as a procedure resulting in TIMI grade 0–2 flow, 
regardless of the residual stenosis [15]. A 12-lead 
electrocardiogram was performed 60 min after 
the procedure in order to evaluate ST-segment 
resolution > 50%.
On ICCU admission, after PCI, in a fasting blood 
sample, the following parameters were measured: 
www.cardiologyjournal.org 307
Serafina Valente et al., Thrombus aspiration in STEMI
troponin I [ng/mL] and hemoglobin [g/L]. Creatinine 
[mg/dL] was also measured in order to calculate 
glomerular filtration rate (GFR) [mL/min/1.73 m2]. 
Troponin I (TnI) was measured 3 times a day 
throughout ICCU stay and peak TnI was considered. 
Transthoracic 2-dimensional echocardiography was 
performed in order to measure left ventricular ejec-
tion fraction (LVEF) on admission and at discharge.
Major bleedings were defined according to the 
TIMI criteria [16]. Patients were diagnosed with 
acute kidney injury if they had a serum creatinine 
value increase of ≥ 1.5-fold over the admission 
value within ICCU-stay [17].
The primary study outcomes were the mortal-
ity at 30-day and at 1-year follow-up. Post discharge 
mortality was computed as the ratio of the number 
of patients who died between discharge, 30-day and 
1-year, and the total number of those discharged 
alive [18]. Most of patients were examined in the 
outpatient clinic at 30-day, 6-month and 1-year 
since the discharge otherwise they were contacted 
via telephone.
The study protocol was set up in accordance 
with the Declaration of Helsinki and approved 
by the local Ethics Committee. An oral informed 
consent for PCI was obtained in all the conscious 
patients and a written consent in the vast majority 
of patients according to their clinical conditions.
Statistical analysis
Statistical analysis was conducted with IBM 
SPSS 20.0 for Windows software (SPSS Inc, Chi-
cago, IL). The primary outcome for the current anal-
ysis was 30-day and 1-year all cause mortality. To 
determine the effect of thrombus aspiration on the 
primary outcome, we first undertook an unadjusted 
Kaplan-Meier comparison. Cox regression analysis 
was performed to determine the hazard ratio (HR) 
for 30-day and 1-year mortality. Since patients were 
not randomly assigned to either adjunctive thrombus 
aspiration or conventional PCI, we applied propen-
sity score matching to adjust for differences in base-
line characteristics between patients treated with 
and without thrombus aspiration. The propensity 
score is a conditional probability of receiving throm-
bus aspiration given a set of observed co-variables. 
A multivariate logistic regression model was used 
to estimate propensity scores, with the two groups 
(i.e., thrombus aspiration vs. conventional PCI) as 
dependent variable and potential confounders as co-
variates. We identified 14 candidate variables poten-
tially related to the use of thrombus aspiration [19]. 
All these variables were included in the propensity 
score estimation model: age, culprit vessel, number 
of vessels diseased, TIMI flow pre PCI, Killip class, 
total ischemic time, stent diameter, stent length, 
LVEF, admission troponin, hypertension, diabetes, 
smoking habit, chronic renal failure. Patients with 
one or more missing variables were excluded. Ulti-
mately, the propensity model was derived in a cohort 
of 1,400 patients. We used the coefficients returned 
by the model to calculate a propensity score for all 
patients enrolled. The propensity-matched cohort 
was established by matching each individual case 
treated with thrombus aspiration in random order to 
the patient from the control group with the closest 
propensity score.
Results
Our series comprises 1,493 consecutive STEMI 
patients all submitted to pPCI. Of these, 93 were 
removed from the analysis because they had at 
least one missing data among variables used for 
matching. This resulted in a final study cohort of 
1,400 patients. Of these, 744 (53.1%) were treated 
with adjunctive thrombus aspiration.
Characteristics of the full cohort
Patients treated with adjunctive thrombus 
aspiration differed significantly in clinical and 
procedural characteristics from those treated with 
conventional PCI (Table 1, left columns). Patients 
treated with thrombus aspiration were younger and 
had a lower LVEF at ICCU admission. The median 
TnI peak was almost double in the thrombus aspi-
ration group. The infarct-related artery was more 
often occluded in the thrombus aspiration while 
the incidence of multivessel disease was higher in 
the conventional PCI group. Lesion predilatation 
was more often performed in the conventional PCI 
group where patients were treated with a smaller 
stent diameter while there was no difference in the 
total stent length. Finally, manual thrombus aspira-
tion using Export was used in 594 (79.8) patients 
out of the 744 who underwent thrombectomy.
Characteristics of the propensity  
matched cohort
The propensity model yielded 6 statistically 
significant independent predictors for thrombus 
aspiration (Table 2). The c-statistic for the model 
was 0.86 (95% CI 0.83–0.90, p < 0.001). The pro-
pensity score analysis selected 724 well-matched 
pairs. The clinical and procedural characteristics 
are showed in Table 1 (right columns). The only 
baseline difference was the persistence of a higher 
incidence of total occluded vessels in the thrombus 
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Figure 1. Time-to-event curves in patients treated with thrombus aspiration or conventional percutaneous coronary 
intervention (PCI); A. Survival analysis in the overall population; B. Survival analysis in the propensity matched cohort; 
HR — hazard ratio; CI — confidence interval.
Table 2. Predictors of thrombus aspiration.
Odds ratio 95% confidence interval P
Age 0.99 0.98–1.00 0.193
Culprit vessel* 0.90 0.76–1.06 0.208
Number of vessels diseased** 0.55 0.46–0.66 < 0.001
TIMI flow pre PCI (1 unit step) 0.44 0.36–0.54 < 0.001
Killip class (1 class step) 0.95 0.79–1.14 0.595
Total ischemic time (1 min step) 0.999 0.999–1.000 0.169
Average stent diameter (1 mm step) 4.69 3.20–6.87 < 0.001
Average stent length (1 mm step) 1.00 0.99–1.01 0.823
Admission LVEF (1% step) 0.98 0.96–1.00 0.016
Troponin I (10 ng/µL step) 1.03 1.02–1.04 < 0.001
Hypertension 0.84 0.63–1.11 0.211
Diabetes 1.01 0.72–1.40 0.957
Ever smoking 1.21 0.90–1.63 0.203
Chronic renal failure 0.41 0.21–0.81 0.010
*Coded as follows: RCA = 1, LCX = 2, LAD = 3, LM = 4, GRAFT = 5; **Coded as follows: 1 vessel = 1, 2 vessels = 2, 3 vessels = 3;  
RCA — right coronary artery; LCX — left circumflex; LAD — left anterior descending; LM — left main; TIMI — Thrombolysis In Myocardial  
Infarction; PCI — percutaneus coronary intervention; LVEF — left ventricular ejection fraction
aspiration group and a higher TnI peak during ICCU 
stay. Lesion predilatation was still more frequent 
in the conventional PCI group while GP IIb/IIIa 
inhibitors were more often used in the thrombus 
aspiration group.
Outcome in the full cohort
The Kaplan-Maier curves are given in Figure 1A. 
Sixty-six (4.7%) patients died during ICCU stay 
(conventional PCI: n = 33, 5.0% vs. thrombus 
aspiration: n = 33, 4.4%; p = NS) and 58 (4.3%) 
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patients were lost at follow-up (conventional PCI: 
n = 26, 4.2% vs. thrombus aspiration: n = 32, 
4.5%; p = NS). Therefore, follow-up analysis was 
performed on 597 patients in the conventional PCI 
group and 679 in the thrombus aspiration group. 
At 30-day 2.8% of patients in the conventional 
PCI group died compared to 2.1% in the thrombus 
aspiration group while at 1-year the corresponding 
figures were 10.6% and 6.2%, respectively. The 
unadjusted HR for 30-day mortality was 0.73 (95% 
CI 0.34–1.58, p = 0.428).
At 1-year follow-up the unadjusted HR for 
mortality was 0.61 (95% CI 0.39–0.94, p = 0.025) 
while the adjusted HR for age, admission TnI, 
diabetes, estimated GFR, admission hemoglobin 
and number of vessels diseased was 0.67 (95% CI 
0.42–1.07, p = 0.094).
Outcome in the propensity matched cohort
In the propensity matched cohort, 22 (3.0%) 
patients died during ICCU stay (conventional 
PCI: n = 13, 3.6% vs. thrombus aspiration: n = 9, 
2.5%; p = NS). Twenty-five (3.6%) patients were 
lost at follow-up (conventional PCI: n = 14, 4.0% 
vs. thrombus aspiration: n = 11, 3.1%; p = NS). 
The follow-up analysis was performed over 335 
patients in the conventional PCI group and 342 in 
the thrombus aspiration group. At 30-day follow-
-up 6.3% of patients in the conventional PCI group 
died compared to 4.7% in the thrombus aspiration 
group. The unadjusted HR for 30-day mortality in 
the propensity matched cohort was 1.01 (95% CI 
0.33–3.14, p = 0.985) (Fig. 1B). At 1-year, among 
the conventional PCI group 10.7% of patients 
died compared to 5.2% in the thrombus aspiration 
group. The 1-year unadjusted HR for mortality 
was 0.47 (95% CI 0.25–0.90, p = 0.022). The HR 
changed significantly and was no more significant 
after adjustment for differences in the use of GP 
IIb/IIIa inhibitors, lesion pre-dilatation and pre-
procedural TIMI flow: 0.71 (95% CI 0.36–1.39, 
p = 0.322) (Table 3).
Discussion
The main finding of the present investigation 
is that adjunctive thrombus aspiration was not 
associated with any significant effect at 30-day 
follow-up, although 1-year mortality was signifi-
cantly lower in the adjunctive thrombus aspiration 
PCI group than in the conventional PCI group. In 
a propensity matched cohort, adjunctive treatment 
with thrombus aspiration resulted in an unadjusted 
HR of 0.47 for 1-year mortality. However, this 
value was considerably altered by the concomitant 
administration of GP IIb/IIIa inhibitors.
These results need to be considered in the 
context of previous studies. Data either from 
large real world STEMI registries or randomized 
trials have not provided conclusive results so far. 
In a recent investigation [20] including 1,035 con-
secutive patients, manual aspiration, performed 
in the 18.3%, was associated with no difference in 
outcome at 30-day and 1-year, respectively. Similar 
results were reported by Kilic et al. [21]. On the 
contrary, in two large real world registries, throm-
bus aspiration was associated with long-term clini-
cal benefit [22, 23]. Data from randomized trials are 
even more inconclusive and meta-analyses are not 
able to shed light on the real efficacy of thrombec-
tomy. Some are showing mortality benefit [24, 25], 
whereas others have shown no significant effect 
[26, 27]. Moreover, in the recent TASTE trial [10], 
performed in a large sample size (7,244 STEMI 
patients), routine thrombus aspiration before PCI 
as compared with PCI alone did not reduce 30-day 
mortality among patients with STEMI. However, 
it may be supposed that the potential benefit of 
thrombus aspiration may not be captured at 30-day 
but may be expected to emerge during the first 
year after infarction. Indeed, it was not until 1-year 
follow-up that a significant difference in mortality 
emerged in TAPAS trial [28].
In this context, our study confirmed the lack of 
short-term benefit from adjunctive thrombus aspi-
ration. The fact that mortality was not reduced with 
Table 3. Adjusted Cox regression analysis for 1-year post discharge mortality in the propensity 
matched cohort.
Adjusted hazard ratio 95% confidence interval P
Thrombus aspiration 0.71 0.36–1.39 0.322
Balloon predilatation 1.40 0.65–3.05 0.386
Pre procedural TIMI flow 1.18 0.61–2.27 0.633
Glycoprotein IIb/IIIa inhibitors 0.25 0.13–0.45 0.001
TIMI — Thrombolysis In Myocardial Infarction
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thrombus aspiration within the first 30-days but 
only afterwards suggests that the initial myocardial 
insult may dictate the early prognosis (as a result 
of heart failure and arrhythmic complications) due 
to the large amount of myocardium at risk, as sug-
gested by the almost double value of TnI peak in 
the thrombectomy group. A similar conclusion is 
also suggested by the fact that the propensity score 
matching selected a population with an higher 
30-day overall mortality rate (5.5% vs. 2.4%) not 
affected by adjunctive thrombus aspiration. On 
the contrary, in this population, at high short-term 
risk, thrombus aspiration may improve the late 
survival mainly by preventing distal embolization 
and permanent microvessel damage. The role of 
microvessel salvage has been recently highlighted 
by Cuculi et al. [29] who demonstrated that positive 
changes of the coronary microcirculation in the first 
day after pPCI, as assessed using invasive index, 
are associated with myocardial salvage and better 
6-month ejection fraction.
The role of GP IIb/IIIa inhibitors in determin-
ing the late survival benefit observed in our study 
among patients treated with thrombus aspiration 
should not be underestimated. The propensity 
matching selection was aimed at avoiding any pre-
treatment confounder [19] and was not performed 
in order to highlight the effects of different treat-
ments. However, the multivariate analysis, which 
was performed in order to assess the impact of 
concomitant treatments on the long-term benefit, 
showed an important role of GP IIb/IIIa inhibitors. 
Both thrombus aspiration and GP IIb/IIIa inhibitors 
may have a role in preventing capillary block of the 
distal vascular bed due to embolization of thrombus 
and friable atheromatous debris which is thought to 
be ubiquitous after pPCI in STEMI. In the INFUSE 
AMI trial [11, 30], intralesional abciximab resulted 
in a modest reduction in infarct size, whereas in-
farct size was unaffected by thrombus aspiration 
and no significant differences in either ischemic or 
heart failure event rates were present with either 
therapy at 30-day follow-up. However, intralesional 
abciximab, thrombus aspiration, or both therapies 
before stent implantation were strongly associated 
with reduced 1-year rates of heart failure, stent 
thrombosis, and death compared with stenting 
alone. Consistently with these results, our study 
suggests a possible synergistic effect of the two 
treatments. Although caution is warranted given 
the retrospective nature of our study and the small 
INFUSE-AMI’s sample size, these observations 
suggest that different synergistic mechanisms may 
underlie the potential clinical benefit of thrombus 
aspiration and GP IIb/IIIa inhibitors. In perspec-
tive, the micronet mesh-covered stent [31] is 
a promising third option in the prevention of distal 
embolization and a large-scale pivotal trial with 
this device has recently begun (NCT01869738).
Limitations of the study
Our study has several limitations. First, the 
study design was a non-randomized observational 
cohort study. We used rigorous adjustments for 
confounding factors, such as propensity score 
matching and multivariate analyses. While these 
statistical methods were used to eliminate dif-
ferences in observed confounders that affected 
a patients’ risk profile, they are unable to account 
for differences in unobserved confounders. A sec-
ond limitation of our study is that we had no data 
on surrogate endpoints such as myocardial blush 
grade, ST-segment resolution, or infarct size. Such 
parameters could have reflected the assumed mode 
of action of aspiration catheters and could have sup-
ported the hypothesis that the observed mortality 
benefit was attributable to adjunctive thrombus 
aspiration. Finally, we did not take into account 
the possible modifications in the clinical treatment 
during the period of enrollment. The results from 
ongoing large-scale trials powered for mortality 
will determine whether thrombus aspiration before 
pPCI is indeed of clinical benefit (NCT01093404 
and NCT01149044).
Conclusions
Adjunctive thrombus aspiration does not influ-
ence 30-day mortality while it is associated with 
1-year survival benefit. This effect seems more 
evident in patients at higher short-term risk. GP 
IIb/IIIa inhibitors and thrombus aspiration may 
have an important synergistic role in leading to the 
long-term benefit. Our observations merit confir-
mation in currently enrolling large randomized tri-
als powered for detecting a difference in mortality.
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